Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy

Affiliations

• ¹ Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece [email protected].
• ² Hematology Section of the First Department of Propedeutic Internal Medicine, Laikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, Greece.
• ³ Service D'Hématologie Clinique et Thérapie Cellulaire CHU (University Hospital), Amiens, France.
• ⁴ Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece.
• ⁵ Theagenion Cancer Center, Department of Hematology, Thessaloniki, Greece.
• ⁶ University of Patras, Hematology Division, Patras, Greece.
• ⁷ University of Ioannina, Hematology Division, Ioannina, Greece.
• ⁸ Peripheral General Anticancer Hospital-Metaxa, Department of Hematology, Piraeus, Greece.
• ⁹ Evangelismos Hospital, Hematology Department, Athens, Attica, Greece.
• ¹⁰ St Savvas Oncology Hospital, Hematology Division, Athens, Greece.
• ¹¹ G.Gennimatas General Hospital, Department of Hematology, Athens, Greece.
• ¹² Department of Haematology, Nicosia General Hospital, Cyprus, Greece.
• ¹³ Henry Dunant Hospital, Hematology Division, Athens, Greece.
• ¹⁴ Department of Pathophysiology, National And Kapodistrian University of Athens, School of Medicine, Greece.
• ¹⁵ Democritus University of Thrace, Alexandroupolis, Greece.